White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances
Posted inClinical Updates Neurology news Radiology

White Matter Microstructure and Cognitive Decline in Aging and Alzheimer Disease: A Comprehensive Review of Recent Advances

This review synthesizes recent large-scale multi-cohort studies revealing white matter microstructural abnormalities—especially free water increases—in limbic tracts as critical markers of cognitive decline in aging and Alzheimer's disease, emphasizing integrated biomarker approaches.
Phenylephrine Versus Norepinephrine in Acute Abdomen Surgery: Similar Clinical Outcomes but Different Early Renin Responses — Implications for Perioperative Hemodynamic Care
Posted inAnesthesiology Critical Care news

Phenylephrine Versus Norepinephrine in Acute Abdomen Surgery: Similar Clinical Outcomes but Different Early Renin Responses — Implications for Perioperative Hemodynamic Care

A randomized trial in 156 emergency acute-abdomen patients found phenylephrine and norepinephrine produced similar postoperative RAAS changes and complication rates; norepinephrine produced an early renin rise, while high preoperative renin predicted greater vasopressor needs and higher AKI incidence.
Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort
Posted inCritical Care news Respiratory

Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort

In a 497,185‑patient registry study, frailty (CFS ≥5) was common and associated with substantially higher in‑hospital mortality across all severities of acute hypoxemic respiratory failure (AHRF). The relationship between PaO2/FiO2 and death was nonlinear and distinctly separated by frailty category.
Why Emergency Medicine Residents Rarely Choose Surgical Critical Care — A Nationwide Survey and a Roadmap to Increase EM-SCC Matriculation
Posted inCritical Care Emergency Medicine news

Why Emergency Medicine Residents Rarely Choose Surgical Critical Care — A Nationwide Survey and a Roadmap to Increase EM-SCC Matriculation

A national survey of 111 emergency medicine trainees identifies limited exposure to surgical critical care, institutional and geographic factors, and program characteristics (ECMO, multidisciplinary teams) as key modifiable drivers of low EM matriculation into surgical critical care fellowships.
Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis
Posted innews Oncology Pediatrics

Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis

A CCSS analysis of 25,723 five-year childhood cancer survivors shows clear dose-response relationships between colorectum-specific radiation dose, irradiated colorectal volume, several chemotherapy exposures (notably procarbazine, high alkylator and platinum doses), and subsequent colorectal cancers, with actionable implications for RT planning and survivorship surveillance.
Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Posted inHematology-Oncology news Oncology

Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low rates of clinically significant cytokine release syndrome and improved patient‑reported outcomes.
Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk
Posted inHematology-Oncology news

Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk

In a randomized Phase II trial, replacing MMF with post‑transplant cyclophosphamide (PTCy) alongside sirolimus and cyclosporine in unrelated donor PBSC transplants markedly lowered chronic GVHD and improved 1‑year chronic GVHD‑free relapse‑free survival, without increasing relapse or early mortality, though severe infections rose.
Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial
Posted inHematology-Oncology news

Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial

In the randomized, double‑blind phase II QUIWI trial, adding quizartinib to standard induction/consolidation chemotherapy and single‑agent maintenance significantly improved event‑free survival and overall survival for adults 18–70 years with newly diagnosed FLT3‑ITD–negative AML versus placebo.
Tiêm thuốc tiêu sợi huyết muộn – Trước khi chuyển đến nơi tiến hành cắt khối máu đông – Có thể cải thiện kết quả ở AIS-LVO: Bằng chứng từ một nhóm 20 trung tâm Pháp
Posted innews

Tiêm thuốc tiêu sợi huyết muộn – Trước khi chuyển đến nơi tiến hành cắt khối máu đông – Có thể cải thiện kết quả ở AIS-LVO: Bằng chứng từ một nhóm 20 trung tâm Pháp

Một nghiên cứu hồi cứu đa trung tâm cho thấy việc tiêm thuốc tiêu sợi huyết qua tĩnh mạch (IVT) bắt đầu sau 4,5 giờ và trước khi chuyển viện để thực hiện can thiệp mạch máu (EVT) liên quan đến tỷ lệ tái thông tự nhiên cao hơn trong quá trình chuyển viện và kết quả chức năng tốt hơn sau 3 tháng mà không tăng tỷ lệ xuất huyết.
Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
Posted innews Oncology

Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results

The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrahepatic cholangiocarcinoma, surpassing historical gem‑cis cohorts.
Ifinatamab Deruxtecan Hiển Thị Hoạt Động Hứa Hẹn ở Bệnh Phổi Tiểu Hạt Diện Rộng Đã Điều Trị Trước: Phân Tích Chính của Thử Nghiệm Giai Đoạn II IDeate-Lung01
Posted innews

Ifinatamab Deruxtecan Hiển Thị Hoạt Động Hứa Hẹn ở Bệnh Phổi Tiểu Hạt Diện Rộng Đã Điều Trị Trước: Phân Tích Chính của Thử Nghiệm Giai Đoạn II IDeate-Lung01

Trong thử nghiệm giai đoạn II IDeate-Lung01, ifinatamab deruxtecan (I-DXd) liều 12 mg/kg mỗi 3 tuần đã đạt tỷ lệ đáp ứng khách quan xác nhận (ORR) là 48,2% và thời gian sống không tiến triển trung bình (PFS) là 4,9 tháng ở bệnh phổi tiểu hạt diện rộng đã điều trị trước (ES-SCLC), với tỷ lệ bệnh phổi kẽ liên quan đến điều trị được đánh giá là 12,4%. Kết quả hỗ trợ phát triển tiếp theo với việc giám sát cẩn thận bệnh phổi kẽ.